Ovarian Cancer Biomarkers: Current Options and Future Promise
Authors:
- 1 September 2008
- journal article
- review article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 6 (8) , 795-802
Abstract
As more effective, less toxic cancer drugs reach patients, the need for accurate and reliable cancer diagnostics and prognostics has become widely appreciated. Nowhere is this need more dire than in ovarian cancer; here most women are diagnosed late in disease progression. The ability to sensitively and specifically predict the presence of early disease and its status, stage, and associated therapeutic efficacy has the potential to revolutionize ovarian cancer detection and treatment. This article reviews current ovarian cancer diagnostics and prognostics and potential biomarkers that are being studied and validated. Some of the most recent molecular approaches being used to identify genes and proteins are presented, which may represent the next generation of ovarian cancer diagnostics and prognostics.Keywords
This publication has 74 references indexed in Scilit:
- MicroRNA Signatures in Human Ovarian CancerCancer Research, 2007
- Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.2007
- Let-7 expression defines two differentiation stages of cancerProceedings of the National Academy of Sciences, 2007
- Whole Genome Oligonucleotide-Based Array Comparative Genomic Hybridization Analysis Identified Fibroblast Growth Factor 1 As a Prognostic Marker for Advanced-Stage Serous Ovarian AdenocarcinomasJournal of Clinical Oncology, 2007
- Osteopontin in metastatic lesions as a prognostic marker in ovarian cancersJournal of Biomedical Science, 2007
- MicroRNA expression and function in cancerTrends in Molecular Medicine, 2006
- Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancerGynecologic Oncology, 2006
- Evaluation of Apolipoprotein A1 and Posttranslationally Modified Forms of Transthyretin as Biomarkers for Ovarian Cancer Detection in an Independent Study PopulationCancer Epidemiology, Biomarkers & Prevention, 2006
- microRNAs exhibit high frequency genomic alterations in human cancerProceedings of the National Academy of Sciences, 2006
- Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian CancerClinical Cancer Research, 2006